ClinicalTrials.gg
TerminatedNCT04049097Updated Sep 15, 2023Results posted

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

A Phase 3 interventional study of Arimoclomol in Inclusion Body Myositis, sponsored by ZevraDenmark. Terminated at 12 sites in 2 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by ZevraDenmark · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
As a consequence of the results of IBM4809 which did not meet any of its efficacy endpoints. The planned duration of open-label treatment was 40 months. After termination, the actual mean duration of treatment was approx. 28 weeks.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Not applicable
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Enrollment
7th of 27
121 · median 24
Started
2019
with 1 other
Phase 3
3 of 37
none open now
Registered
26th of 37
by date
Lead sponsor
2 of 37
ZevraDenmark

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 in phase 3, and was the 26th registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)

Read the detailed description

This was planned to be a 40-month open-label extension trial of the 20-month randomized, double-blind, placebo-controlled IBM4809 trial. The open-label trial was terminated early by the sponsor as a consequence of the results of IBM4809 which did not meet any of its efficacy endpoints. Therefore, the actual average duration of open-label treatment was approximately 28 weeks.

03

Conditions studied

  • Inclusion Body Myositis

Keywords

  • IBM
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to comprehend and is willing to provide written and is capable and willing to comply with trial procedures.
  2. Patient has completed the IBM4809 trial on treatment with Medicinal Product (IMP).

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy or intolerance to arimoclomol or its constituents.
  2. Exposure to any other treatment within 30 days or \<5 half-lives of the baseline visit or taking part or planning to take part in another interventional trial.
  3. Significant protocol deviation in the blinded IBM4809 trial based on the investigator's judgement in discussion with the medical monitor.
  4. Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for female participants until 4 weeks after last dose and for male participants up to 3 months after last dose. Premenopausal women must have a negative pregnancy test prior to dosing with trial medication. Acceptable methods of birth control are:

    • Hormonal methods associated with inhibition of ovulation such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before arimoclomol administration.
    • Total abstinence from sexual intercourse since the last menses before arimoclomol administration. (The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence [calendar, symptothermal, post-ovulation] methods are not acceptable methods of contraception).
    • Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
  5. Any concurrent condition that in the investigator's opinion will significantly interfere with assessment of safety or efficacy.
  6. Inability to comply with the protocol-specified procedures/evaluations and scheduled visits as per the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Arimoclomol

    248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily

    Drug: Arimoclomol

Interventions

  • 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime

06

What researchers measure

Primary outcomes

  1. Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score

    The Inclusion Body Myositis Functional Rating Scale (IBMFRS) includes 10 measures (swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs), each graded on a Likert scale from 0 (being unable to perform) to 4 (normal). The sum of the 10 items gives a value between 0 and 40. A higher score represents less functional limitation. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

    Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).

Secondary outcomes

  1. Change in Six Minutes Walking Distance Test; Distance at 6 Minutes (6MWD)

    Patients were instructed to walk down one side of a track and back along the opposite side as quickly and safely as possible for 6 minutes. Patients were allowed to take breaks as needed during the walking period, but timing continued during breaks. The distance walked in meters was recorded after 6 minutes. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

    Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).

  2. Change in Modified Timed Up and Go (mTUG)

    The Modified Timed Up and Go (mTUG) measures the patient's ability to get up from a chair (allowing patients to use their arms), walk 3 meters, turn around, walk back to the chair, and sit down. The use of nearby walls or assistance from a caregiver was not allowed. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

    Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).

  3. Change in Quadriceps Muscle Strength

    Maximal voluntary isometric contraction testing (MVICT) of the patient's quadriceps muscle (extensor strength of the knee) were performed using a hand myometer which is a hand-held device that allows the examiner to push against a muscle while the patient resists. The test was performed on each side. The results for the stronger knee are reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

    Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).

  4. Change in Hand Grip Strength

    Hand grip strength was assessed using a dynamometer. The test was performed on each hand. The grip strength of the stronger hand is reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

    Time frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).

  5. Change in the 36-Item Short Form Health Survey (SF-36)

    The 36-Item Short Form Health Survey (SF-36) is a 36-item, patient-reported survey of health status. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No derived scores were calculated for SF-36 and no summary tabulation was done.

    Time frame: Change from Baseline in IBM-OLE to Early Termination Visit

  6. Number of Falls and Near Falls

    Patients recorded the number of falls and near falls in a falls diary. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No tabulation of falls and near falls was performed.

    Time frame: Baseline to Early Termination Visit

07

Results

Posted Sep 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneArimoclomol (Open-label)
Started121
Completed0
Not completed121
Withdrew: Adverse event18
Withdrew: Death2
Withdrew: Lost to follow-up1
Withdrew: Physician decision2
Withdrew: Withdrawal by subject9
Withdrew: Protocol violation2
Withdrew: Other1
Withdrew: The trial was terminated early by the sponsor86

Outcome measures

PrimaryChange in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score

The Inclusion Body Myositis Functional Rating Scale (IBMFRS) includes 10 measures (swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs), each graded on a Likert scale from 0 (being unable to perform) to 4 (normal). The sum of the 10 items gives a value between 0 and 40. A higher score represents less functional limitation. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

Time frame:
Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Reported as:
Mean · score on a scale
Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score
score on a scaleArimoclomol (Open-label)
Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score-1.7 ± 2.60
SecondaryChange in Six Minutes Walking Distance Test; Distance at 6 Minutes (6MWD)

Patients were instructed to walk down one side of a track and back along the opposite side as quickly and safely as possible for 6 minutes. Patients were allowed to take breaks as needed during the walking period, but timing continued during breaks. The distance walked in meters was recorded after 6 minutes. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

Time frame:
Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Reported as:
Mean · meters
Change in Six Minutes Walking Distance Test; Distance at 6 Minutes (6MWD)
metersArimoclomol (Open-label)
Change in Six Minutes Walking Distance Test; Distance at 6 Minutes (6MWD)-17.2 ± 61.06
SecondaryChange in Modified Timed Up and Go (mTUG)

The Modified Timed Up and Go (mTUG) measures the patient's ability to get up from a chair (allowing patients to use their arms), walk 3 meters, turn around, walk back to the chair, and sit down. The use of nearby walls or assistance from a caregiver was not allowed. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

Time frame:
Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Reported as:
Mean · meters/second
Change in Modified Timed Up and Go (mTUG)
meters/secondArimoclomol (Open-label)
Change in Modified Timed Up and Go (mTUG)-0.027 ± 0.0847
SecondaryChange in Quadriceps Muscle Strength

Maximal voluntary isometric contraction testing (MVICT) of the patient's quadriceps muscle (extensor strength of the knee) were performed using a hand myometer which is a hand-held device that allows the examiner to push against a muscle while the patient resists. The test was performed on each side. The results for the stronger knee are reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

Time frame:
Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Reported as:
Mean · kg
Change in Quadriceps Muscle Strength
kgArimoclomol (Open-label)
Change in Quadriceps Muscle Strength-0.48 ± 3.719
SecondaryChange in Hand Grip Strength

Hand grip strength was assessed using a dynamometer. The test was performed on each hand. The grip strength of the stronger hand is reported here. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol and data were only summarized descriptively.

Time frame:
Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).
Reported as:
Mean · kg
Change in Hand Grip Strength
kgArimoclomol (Open-label)
Change in Hand Grip Strength-0.23 ± 4.616
SecondaryChange in the 36-Item Short Form Health Survey (SF-36)

The 36-Item Short Form Health Survey (SF-36) is a 36-item, patient-reported survey of health status. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No derived scores were calculated for SF-36 and no summary tabulation was done.

Time frame:
Change from Baseline in IBM-OLE to Early Termination Visit

No measurements were reported for this outcome.

SecondaryNumber of Falls and Near Falls

Patients recorded the number of falls and near falls in a falls diary. After the study was terminated early by the sponsor, the analyses of the efficacy endpoints were simplified from what was planned in the study protocol. No tabulation of falls and near falls was performed.

Time frame:
Baseline to Early Termination Visit

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events (AEs) were collected from the first dose of study medication until 14 days following the latest administration of study medication. AEs were assessed monthly for the first 6 months, and then every second or third month. The time frame for collection of AEs was from Baseline in IBM-OLE to Early Termination (variable, an average of approximately 28 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arimoclomol (Open-label)2/121 (1.7%)13/121 (10.7%)97/121 (80.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventArimoclomol (Open-label)
Corona virus infectionInfections and infestations2/121
Transaminases increasedInvestigations2/121
PneumoniaInfections and infestations1/121
Electrocardiogram abnormalInvestigations1/121
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/121
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/121
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/121
Crohn's diseaseGastrointestinal disorders1/121
Large intestine perforationGastrointestinal disorders1/121
Disease progressionGeneral disorders1/121
Most frequent other events
Showing 10 of 11
Most frequent other events
EventArimoclomol (Open-label)
ConstipationGastrointestinal disorders15/121
Alanine aminotransferase increasedInvestigations14/121
Aspartate aminotransferase increasedInvestigations13/121
DiarrhoeaGastrointestinal disorders13/121
Transaminases increasedInvestigations10/121
Gamma-glutamyltransferase increasedInvestigations10/121
InsomniaPsychiatric disorders9/121
NauseaGastrointestinal disorders8/121
ContusionInjury, poisoning and procedural complications7/121
Blood lactate dehydrogenase increasedInvestigations7/121

Baseline characteristics

Safety population: All patients who received at least 1 dose or partial dose of arimoclomol in IBM-OLE.

Age, Continuous
Age, Continuous(years)Arimoclomol (Open-label)
Mean66.2 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)Arimoclomol (Open-label)
Female23
Male98
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arimoclomol (Open-label)
American Indian or Alaska Native0
Asian3
Black or African American1
Native Hawaiian or Other Pacific Islander0
White115
Other2
Multiple0
Age at diagnosis
Age at diagnosis(years)Arimoclomol (Open-label)
Mean62.3 ± 8.02
08

Study locations

12 sites
  • Phoenix Neurological Associates
    Phoenix, Arizona 85018, United States
  • University of California
    Irvine, California 92697, United States
  • University of Colorado School of Medicine
    Aurora, Colorado 80045, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins University
    Baltimore, Maryland 21218, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • The Ohio State University
    Columbus, Ohio 43221, United States
  • Nerve and Muscle Center of Texas
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • University College of London
    London, WC1N 3BG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Nov 2021, 29 months.

Results were first posted in Sep 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2019
First posted
Aug 7, 2019
StartActual
May 20, 2019
Primary completionActual
Nov 15, 2021
CompletionActual
Nov 15, 2021
Results first posted
Sep 15, 2023
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04049097
Lead sponsor
ZevraDenmark
Responsible party
Sponsor
First posted
Aug 7, 2019
Start date
May 20, 2019
Primary completion
Nov 15, 2021
Completion
Nov 15, 2021
Results posted
Sep 15, 2023
Last update
Sep 15, 2023

Study contacts

Mazen M Dimachkie
principal investigator · University of Kansas Medical Center
Michael Hanna
principal investigator · University College, London

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arimoclomol

Start the discussion